VRXA News

VERAXA Biotech (NASDAQ: VRXA) is developing a new generation of antibody-based cancer therapies at a time when oncology research is increasingly focused on a difficult question: how can powerful treatments be made more selective without sacrificing their ability to kill cancer cells? The wiss biotechnology company is approaching that problem through a portfolio of antibody-drug […]

VERAXA Biotech Designates Raju Willener as CFO...

VERAXA Biotech (NASDAQ: VRXA) a developer of next-generation antibody-based cancer therapies, announced the appointment of Raju Willener as chief financial officer, effective immediately. Willener brings more than three decades of international financial leadership experience spanning global capital markets, investment banking, corporate finance, asset management and strategic leadership. He will report to CEO and Co-Founder Christoph Antz, […]

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, and Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, have reached an early research milestone in their collaboration to develop antibody oligonucleotide conjugates (“AOCs”), providing VERAXA with an initial proof point for applying its […]

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has moved its VXA-222 bispecific antibody-drug conjugate program into the next stage of development after completing the initial phase of its collaboration with OmniAb, giving the biotechnology company a new development milestone while it continues expanding the intellectual-property estate underpinning its antibody technology […]

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, is advancing its oncology pipeline with a strategy centered on changing how antibody-based therapies recognize and attack cancer cells. The biotechnology company is developing bispecific antibody-drug conjugates, T-cell engagers and other engineered antibody formats, with its proprietary BiTAC technology providing the distinctive element […]

VERAXA (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has reached another development milestone in its oncology pipeline, announcing that its VXA-222 bispecific antibody-drug conjugate (“bsADC”) program has advanced beyond the discovery phase and into the next stage of development. The milestone reflects continued progress across the company’s therapeutic portfolio as it simultaneously […]

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has appointed antibody therapeutics researcher Christoph Erkel, Ph.D., as Chief Scientific Officer, reinforcing the company’s focus on advancing its proprietary BiTAC(R) technology platform as it prepares its lead oncology programs for clinical development. The announcement comes at a time when the biotechnology company […]

VERAXA Biotech (NASDAQ: VRXA) announced an expansion of its intellectual property portfolio, filing new patent applications during the first half of 2026 covering its next-generation BiTAC-TCE and BiTAC-ADC technology platforms and related therapeutic programs. The company said previously granted patents protecting supporting technologies have also cleared the opposition period, bringing its portfolio to more than 50 […]